Overview
ITM2B-related amyloidosis is a rare genetic disorder characterized by the deposition of amyloid fibrils composed of the protein encoded by the ITM2B gene, leading to organ dysfunction, particularly in the liver and kidneys 1.Diagnosis
Identification of amyloid deposits via Congo red staining and amyloid fibril protein characterization by mass spectrometry or immunohistochemistry targeting ITM2B 1.
Genetic testing for mutations in the ITM2B gene to confirm diagnosis 1.Management
No specific pharmacological treatments are detailed in the provided abstracts; management focuses on supportive care and addressing organ dysfunction 1.
Liver transplantation may be considered for severe liver involvement 1.Special Populations
Limited data in abstracts regarding specific management adjustments for pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Confirm diagnosis through genetic testing for ITM2B mutations and biochemical characterization of amyloid deposits (Evidence: Expert opinion 1).
Implement supportive care measures tailored to organ dysfunction, including renal and hepatic support as needed (Evidence: Expert opinion 1).
Consider liver transplantation for patients with end-stage liver disease secondary to ITM2B-related amyloidosis (Evidence: Expert opinion 1).References
1 Zeheb R, Chang V, Orr GA. An analytical method for the selective retrieval of iminobiotin-derivatized plasma membrane proteins. Analytical biochemistry 1983. link90063-5)